Retatrutide vs Tirzepatide for Sleep Apnea
Obstructive sleep apnea affects 1 billion people worldwide, and obesity is its leading cause. Here is how retatrutide and tirzepatide compare for improving this condition.
Medical Disclaimer: Do not stop CPAP therapy without a follow-up sleep study and provider guidance. This comparison is for informational purposes only.
Sleep apnea is more than snoring — it is a serious condition linked to heart disease, stroke, diabetes, and cognitive decline. Weight loss is the most effective non-surgical treatment, making GLP-1 medications a potential game-changer for millions of CPAP users.
Tirzepatide: The SURMOUNT-OSA Trial
Tirzepatide is the only GLP-1-class medication with a dedicated sleep apnea clinical trial. SURMOUNT-OSA showed approximately 50% reduction in AHI (apnea-hypopnea index) over 52 weeks. Nearly 43% of patients achieved AHI remission (below 5 events per hour). Patients also reported improved sleep quality, daytime alertness, and reduced CPAP usage.
Retatrutide: Theoretical Advantages
Retatrutide does not have dedicated sleep apnea trial data. However, its greater average weight loss (24% vs 22%) suggests potentially greater AHI improvement. The relationship between weight loss and AHI improvement is roughly linear — more weight loss equals more improvement. Additionally, retatrutide's glucagon-mediated energy expenditure increase may reduce neck and pharyngeal fat more effectively.
Side-by-Side Comparison
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Dedicated OSA trial | Yes (SURMOUNT-OSA) | No |
| AHI reduction | ~50% | Estimated greater (more weight loss) |
| Average weight loss | 22% | 24% |
| Availability | Available now | Phase 3 trials |
| Compounded cost (Trimi) | $125/mo | Contact for pricing |
The Bottom Line
Our Assessment
Tirzepatide has proven sleep apnea data from SURMOUNT-OSA. Retatrutide may ultimately produce greater improvement due to more weight loss, but this is speculative until dedicated trials are completed. For sleep apnea patients who need treatment now, tirzepatide is the evidence-based choice.
Frequently Asked Questions
Can GLP-1 medications cure sleep apnea?
Some patients achieve complete resolution of obstructive sleep apnea with sufficient weight loss from GLP-1 medications. The SURMOUNT-OSA trial showed tirzepatide reduced AHI by approximately 50%. Whether this constitutes a 'cure' depends on the severity — mild cases may resolve entirely, while severe cases often improve significantly.
How much weight loss is needed to improve sleep apnea?
Even 10-15% body weight loss can meaningfully improve sleep apnea. A 10% weight loss typically reduces the apnea-hypopnea index (AHI) by 20-30%. Greater weight loss produces proportionally greater improvement.
Which would be better for sleep apnea — retatrutide or tirzepatide?
Both should produce significant improvement through weight loss. Tirzepatide has direct clinical trial data (SURMOUNT-OSA). Retatrutide may produce greater weight loss but has no sleep apnea-specific trial data yet. Either is far better than untreated obesity with sleep apnea.
Can I stop CPAP if I lose enough weight on GLP-1 medication?
Possibly, but only under medical supervision with a follow-up sleep study. Do not stop CPAP independently even if you feel better. A repeat polysomnography can confirm whether your AHI has dropped below the treatment threshold (typically AHI less than 5).
Breathe Easier with Trimi
Compounded tirzepatide from $125/mo or semaglutide from $125/mo. Address the root cause of sleep apnea.
Get Started TodayMore on Micro-Comparisons
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).